Business Description

Aadi Bioscience Inc
NAICS : 325412
SIC : 2834
Compare
Compare
Traded in other countries / regions
3350.GermanyAADI.USA IPO Date
2021-08-27Description
Aadi Bioscience Inc is a clinical-stage biopharmaceutical company developing precision therapies for genetically-defined cancers. Aadi's primary goal is to bring transformational therapies to cancer patients with mTOR pathway driver alterations such as alterations in TSC1 or TSC2 genes, where other mTOR inhibitors have not or cannot be effectively exploited due to problems of pharmacology, effective drug delivery, safety, or effective targeting to the disease site.
Financial Strength
7/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 106.34 | |||||
Equity-to-Asset | 0.87 | |||||
Debt-to-Equity | 0.01 | |||||
Debt-to-EBITDA | -0.03 | |||||
Piotroski F-Score | N/A/9 | |||||
Altman Z-Score | 2.92 | |||||
Beneish M-Score | -4 |
Growth Rank
Name | Current | Vs Industry | Vs History |
---|
Momentum Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 28.57 | |||||
9-Day RSI | 26.85 | |||||
14-Day RSI | 26.27 | |||||
6-1 Month Momentum % | -16.64 | |||||
12-1 Month Momentum % | -37.17 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 10.61 | |||||
Quick Ratio | 10.57 | |||||
Cash Ratio | 10.23 | |||||
Days Inventory | 181.79 | |||||
Days Sales Outstanding | 77.86 | |||||
Days Payable | 1521.19 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History |
---|
Profitability Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 89.87 | |||||
Operating Margin % | -540.82 | |||||
Net Margin % | -569.57 | |||||
ROE % | -45.37 | |||||
ROA % | -39.53 | |||||
ROIC % | -1000.15 | |||||
ROC (Joel Greenblatt) % | -5298.27 | |||||
ROCE % | -43.12 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 13.67 | |||||
PB Ratio | 1.05 | |||||
Price-to-Tangible-Book | 1.05 | |||||
EV-to-EBIT | 0.09 | |||||
EV-to-EBITDA | 0.09 | |||||
EV-to-Revenue | -0.49 | |||||
EV-to-Forward-Revenue | 12.52 | |||||
EV-to-FCF | 0.11 | |||||
Price-to-Net-Current-Asset-Value | 1.08 | |||||
Price-to-Net-Cash | 1.13 | |||||
Earnings Yield (Greenblatt) % | 1111.11 |
How Aadi Bioscience Inc (AADI) Makes Its Money
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:AADI
Peter Lynch Chart
Performance
Dividend
Log
Annualized Return %
Total Annual Return %
Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil $) | 10.989 | ||
EPS (TTM) ($) | -2.98 | ||
Beta | 0 | ||
Volatility % | 35.47 | ||
14-Day RSI | 26.27 | ||
14-Day ATR ($) | 0.528998 | ||
20-Day SMA ($) | 8.7525 | ||
12-1 Month Momentum % | -37.17 | ||
52-Week Range ($) | 7.0001 - 18.54 | ||
Shares Outstanding (Mil) | 24.4 |
Piotroski F-Score Details
Year:
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 9999 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Aadi Bioscience Inc Filings
Document | Form | Filing Date | ||
---|---|---|---|---|
No Filing Data |
Aadi Bioscience Inc Stock Events
Event | Date | Price($) | ||
---|---|---|---|---|
No Event Data |
Aadi Bioscience Inc Frequently Asked Questions
What is Aadi Bioscience Inc(AADI)'s stock price today?
The current price of AADI is $7.29. The 52 week high of AADI is $18.54 and 52 week low is $7.00.
When is next earnings date of Aadi Bioscience Inc(AADI)?
The next earnings date of Aadi Bioscience Inc(AADI) is 2023-03-28.
Does Aadi Bioscience Inc(AADI) pay dividends? If so, how much?
Aadi Bioscience Inc(AADI) does not pay dividend.
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |